Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ.

Area of Science:

• Immunology
• Biomaterials Science
• Cancer Therapy

Background:

• Dendritic cells (DCs) are crucial for initiating T cell responses to clear infections.
• Mimicking infection-induced DC activation is a promising strategy for cancer immunotherapy.

Purpose of the Study:

• To design and evaluate macroporous poly(lactide-co-glycolide) (PLG) matrices as cancer vaccines.
• To investigate the efficacy of releasing inflammatory cytokines (GM-CSF, Flt3L, CCL20) to recruit and activate DCs for anti-tumor immunity.

Main Methods:

• Fabrication of PLG matrices loaded with GM-CSF, Flt3L, or CCL20.
• Assessment of DC recruitment, activation, and T cell priming in a B16-F10 melanoma mouse model.
• Evaluation of therapeutic efficacy, including anti-tumor T cell responses and long-term survival.

Main Results:

• All tested vaccine systems induced specific anti-tumor T cell responses and improved survival.
• GM-CSF and Flt3L loaded scaffolds outperformed CCL20 scaffolds.
• GM-CSF enhanced conventional DC recruitment and activation markers (MHC(II), CD86(+)).
• Flt3L increased plasmacytoid DC (pDC) numbers and T cell-amplifying cytokines.

Conclusions:

• 3D polymer matrices can be engineered to release cytokines and effectively mobilize and activate distinct DC subsets in vivo.
• This approach holds potential for developing novel immunotherapies by modulating DC populations for enhanced anti-tumor T cell responses.